CDH1 and cancer: Currently, most molecularly targeted drugs are inhibitors of driver oncogenes, because it appears more straightforward to repress a hyperactivated oncogene than to restore the function of inactivated tumour suppressor genes.24 Among several promising strategies of drug development for cancer with mutations in tumour suppressor genes, we here applied a comprehensive approach for E-cadherin-deficient DGC, that is, a screening with a collection of well-established annotated compounds.